Company Overview
Snapshot
Founded in January 2006 by Miki Shacham, Situgen Med operates with 1–10 employees. The company has secured funding across two rounds, with RAD BioMed participating as an investor. A significant milestone for Situgen Med was the completion of clinical trials for its umbilical cord blood collection device in September 2008.
Business overview
Situgen Med is a medical device startup specializing in developing a comprehensive system for extracting stem-cell-rich umbilical cord blood. Its core product, the patented SG1040, is a disposable, all-inclusive, and non-contaminating collection kit designed to enhance the quality of cord blood and increase the number of stem cells extracted. This novel, needle-free device prevents the bottleneck effect typically associated with traditional needle-based collection methods. The company operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices industry with its innovative medical technologies.
Strategic signal
In September 2008, Situgen Med completed clinical trials for its revolutionary umbilical cord blood collection device. This milestone signals significant progress in validating the efficacy and safety of its SG1040 system, indicating a move towards commercial readiness and potential market entry for a device designed to improve stem cell collection.
Log in to access full profile ›Company Intelligence Q&A
- When was Situgen Med founded?
- Situgen Med was founded in January 2006.
- Who is the founder of Situgen Med?
- Miki Shacham is the CEO and founder of Situgen Med.
- What is Situgen Med's primary product?
- Situgen Med's primary product is the SG1040, a patented, disposable, and needle-free device designed for the collection of stem-cell-rich umbilical cord blood.
- What significant development occurred in September 2008 for Situgen Med?
- In September 2008, Situgen Med completed clinical trials for its revolutionary device for umbilical cord blood collection.
- Which investor participated in Situgen Med's January 2006 funding round?
- In January 2006, RAD BioMed participated as an investor in.